Cyr Financial Inc. Cuts Stock Holdings in Axon Enterprise, Inc $AXON

Cyr Financial Inc. lowered its position in Axon Enterprise, Inc (NASDAQ:AXON) by 56.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 278 shares of the biotechnology company’s stock after selling 355 shares during the period. Cyr Financial Inc.’s holdings in Axon Enterprise were worth $230,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. TCTC Holdings LLC boosted its stake in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after buying an additional 24 shares during the last quarter. Bartlett & CO. Wealth Management LLC lifted its holdings in Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares during the period. Banque Transatlantique SA purchased a new position in Axon Enterprise in the first quarter worth $31,000. Catalyst Capital Advisors LLC bought a new position in Axon Enterprise in the 1st quarter valued at $32,000. Finally, Flaharty Asset Management LLC bought a new position in Axon Enterprise in the 1st quarter valued at $33,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on AXON. Bank of America raised their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Craig Hallum upgraded shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research note on Tuesday, August 5th. UBS Group reaffirmed a “neutral” rating and issued a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Raymond James Financial reissued an “outperform” rating and set a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Stock Down 0.5%

Axon Enterprise stock opened at $708.84 on Monday. The firm has a 50 day simple moving average of $758.60 and a 200 day simple moving average of $703.76. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 1-year low of $388.37 and a 1-year high of $885.91. The firm has a market capitalization of $55.64 billion, a price-to-earnings ratio of 175.02, a P/E/G ratio of 27.53 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Monday, September 8th. The stock was sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the completion of the sale, the chief executive officer owned 3,043,982 shares of the company’s stock, valued at approximately $2,263,626,774.48. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jennifer H. Mak sold 77 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the transaction, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. The trade was a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,932 shares of company stock valued at $34,408,816 in the last ninety days. 5.70% of the stock is owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.